2023
National Patterns of Early Adoption of Magnetic Resonance Imaging–Guided Linear Accelerators in 2018 to 2019
Yu J, Kinslow C, Cheng S, Ellis R, Horowitz D. National Patterns of Early Adoption of Magnetic Resonance Imaging–Guided Linear Accelerators in 2018 to 2019. Advances In Radiation Oncology 2023, 8: 101167. PMID: 36798607, PMCID: PMC9926207, DOI: 10.1016/j.adro.2022.101167.Peer-Reviewed Original ResearchNational Cancer DatabaseIntensity modulated radiation therapyFood and Drug Administration approvalSite of diseaseImprove radiation treatmentDrug Administration approvalFood and Drug AdministrationSample of patientsRadiation therapyLinear acceleratorCancer DatabaseAdministration approvalDisease sitesRadiation treatmentComprehensive cancer centerAcademic centersCancer CenterDrug AdministrationPatientsPractice patternsTherapyCancer sitesAdapt treatmentImproved visualizationBreast
2020
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, Jilaveanu L, Tran T, Pavlik K, Rowen E, Gerrish H, Komlo A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. The Lancet Oncology 2020, 21: 655-663. PMID: 32251621, PMCID: PMC7380514, DOI: 10.1016/s1470-2045(20)30111-x.Peer-Reviewed Original ResearchConceptsBrain metastasis responseYale Cancer CenterPD-L1 expressionPhase 2 trialUntreated brain metastasesBrain metastasesAdrenal insufficiencyAdverse eventsMetastasis responseCNS diseaseCancer CenterCohort 2Cohort 1Eastern Cooperative Oncology Group performance statusTreatment-related serious adverse eventsModified Response Evaluation CriteriaStage IV NSCLCTreatment-related deathsAcute kidney injuryPD-1 blockadeSerious adverse eventsSolid Tumors criteriaPhase 2 studyProportion of patientsResponse Evaluation Criteria
2016
National sociodemographic disparities in the treatment of high‐risk prostate cancer: Do academic cancer centers perform better than community cancer centers?
Mahal B, Chen Y, Muralidhar V, Mahal A, Choueiri T, Hoffman K, Hu J, Sweeney C, Yu J, Feng F, Kim S, Beard C, Martin N, Trinh Q, Nguyen P. National sociodemographic disparities in the treatment of high‐risk prostate cancer: Do academic cancer centers perform better than community cancer centers? Cancer 2016, 122: 3371-3377. PMID: 27434225, DOI: 10.1002/cncr.30205.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAgedBlack or African AmericanCancer Care FacilitiesCommunity Health ServicesDatabases, FactualDemographyFollow-Up StudiesHealthcare DisparitiesHispanic or LatinoHumansMaleMedically UninsuredNeoplasm GradingNeoplasm StagingPrognosisProstatic NeoplasmsQuality of Health CareRisk FactorsSocioeconomic FactorsUnited StatesWhite PeopleConceptsHigh-risk prostate cancerCommunity cancer centerProstate cancerAcademic cancer centerCancer CenterDefinitive therapyTreatment delayTreatment of high-risk prostate cancerAcademic centersNational Cancer Data BaseMultivariate Cox regression analysisSociodemographic disparitiesHigh-risk cancerCancer treatment patternsMultivariate Cox regressionTiming of therapyCox regression analysisMultivariate logistic analysisTreatment disparitiesCommunity centersExperience treatment delaysUninsured patientsTreatment patternsGray's testCox regression